Our leadership team, including recognized physician experts and researchers, is at the forefront of shaping new standards of cancer care based upon the latest research. Patients are at the heart of everything we do. Sarah Cannon offers integrated cancer services, providing patients with cutting-edge treatments and upholding the highest quality care for patients from diagnosis through survivorship.
Melissa Johnson, MD
Associate Director, Lung Cancer Research
Dr. Johnson joined Sarah Cannon in 2014 and serves as the associate director of lung cancer research. Her responsibilities include supporting the growth of the phase 2/3 Lung Program clinical trial portfolio, while also furthering the development of early phase compounds for thoracic malignancies in the drug development unit.
Johnson received her undergraduate degree from the University of North Carolina, Chapel Hill and her medical degree from the University of Pennsylvania. She completed her residency in internal medicine at New York Presbyterian/Weill Cornell Medical Center and her fellowship in medical oncology and hematology at Memorial Sloan Kettering Cancer Center where she also served as chief fellow for one year. She spent four years as a faculty member at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and Feinberg School of Medicine, where she was a founding member of the Northwestern Medical Developmental Therapeutics Institute (NMDTI). She is board certified in internal medicine and medical oncology. Additionally, she is an associate with Tennessee Oncology, PLLC.